Alleviate crucial challenges in scaling up gene therapy manufacturing

Cell & Gene Therapy Insights 2022; 8(8), 1135;

DOI: 10.18609/cgti.2022.167

Published: 11 September 2022
Emily Moran

  • How CBM’s modular, decoupled unit operations for vector production drive larger production volumes
  • What process mapping from an end-user perspective should impact design strategy
  • How CBM’s flexible “Partner in Plant” model facilitates in-process development and GMP operations in manufacturing suites
  • What progress needs to be made by the industry to accelerate AAV manufacturing at a large scale

Emily Moran has 16+ years in the biopharmaceutical industry having served most recently as Head of Viral Vector Manufacturing at Lonza Houston, one of the largest viral vector manufacturing operations in the world. At Lonza, managed 20+ viral vector programs resulting in the production of 80+ viral vector batches and subsequent drug product fills at 90%+ success rate including the production of 24+ cell banks and viral banks. Before joining Lonza, Emily spent 14 years focused on GMP Commercial Manufacturing at Sanofi Pasteur, where she oversaw the production of over 1,500 viral and bacterial biologics batches, 5000+ media and buffers, and 600 commercial fills delivering doses to 240M patients. Emily holds a BSc from Ursinus College and an MBA. from the New York Institute of Technology